NASDAQ:CLLSCellectis Stock Price, Forecast & News

Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLLS shares have increased by 47.0% and is now trading at $16.80.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cellectis.

Cellectis is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cellectis.

Cellectis SA (NASDAQ:CLLS) issued its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.59) by $1.06. The biotechnology company had revenue of $51.91 million for the quarter, compared to analysts' expectations of $21.07 million. Cellectis had a negative net margin of 89.50% and a negative return on equity of 18.00%.
View Cellectis' earnings history.

7 brokerages have issued 12-month price targets for Cellectis' stock. Their forecasts range from $11.00 to $73.00. On average, they expect Cellectis' stock price to reach $32.17 in the next twelve months. This suggests a possible upside of 91.5% from the stock's current price.
View analysts' price targets for Cellectis.

Media headlines about CLLS stock have been trending positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cellectis earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Cellectis.

Cellectis saw a increase in short interest in June. As of June 30th, there was short interest totaling 359,300 shares, an increase of 39.9% from the June 15th total of 256,900 shares. Based on an average trading volume of 216,100 shares, the short-interest ratio is presently 1.7 days. Currently, 0.9% of the company's stock are sold short.
View Cellectis' Short Interest.

Some companies that are related to Cellectis include Twist Bioscience (TWST), Immunovant (IMVT), Legend Biotech (PCVX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Mesoblast (MESO), Sangamo Therapeutics (SGMO), BAVARIAN NORDIC/S (BVNRY), Revolution Medicines (RVMD), Coherus Biosciences (CHRS), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Cortexyme (CRTX), Regenxbio (RGNX) and Beam Therapeutics (BEAM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Micron Technology (MU), Intellia Therapeutics (NTLA), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (2.53%), Sumitomo Mitsui Trust Holdings Inc. (1.73%), Hudson Bay Capital Management LP (0.38%), New York State Common Retirement Fund (0.25%), Vident Investment Advisory LLC (0.20%) and Vident Investment Advisory LLC (0.20%).

CLLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Sumitomo Mitsui Trust Holdings Inc., Hudson Bay Capital Management LP, UBS Group AG, WS Management Lllp, Vident Investment Advisory LLC, Vident Investment Advisory LLC, and Trexquant Investment LP.

CLLS stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Marshall Wace North America L.P., RMB Capital Management LLC, Exchange Traded Concepts LLC, Princeton Capital Management LLC, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., Bellevue Group AG, and New York State Common Retirement Fund.

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $16.80.

Cellectis has a market capitalization of $713.43 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe.

The official website for Cellectis is www.cellectis.com.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]